Crossmark

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s40880-017-0196-5

Published Online: 2017-03-07

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tan, Qiu-Wen

Luo, Ting

Zheng, Hong

Tian, Ting-Lun

He, Ping

Chen, Jie

Zeng, He-Lin

Lv, Qing
Clinical Trials ^BETA

Clinical trials referenced in this document:

chictr-trc-10001043 at Chinese Clinical Trial Registry

Documents that mention this clinical trial
Funding

Funding for this research was provided by:

Pfizer (WS388465(CHN2008ONC009))

Department of Science and Technology of Sichuan Province (2014SZ0190)
License Information

Text and Data Mining valid from 2017-03-07

Version of Record valid from 2017-03-07
More Information

Article History

Received: 23 May 2016

Accepted: 7 December 2016

First Online: 7 March 2017

Document is current

Any future updates will be listed below